Autolus Therapeutics (NASDAQ:AUTL) Issues Quarterly Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) posted its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21), FiscalAI reports. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. The firm had revenue of $41.24 million during the quarter, compared to analysts’ expectations of $39.54 million.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• AUCATZYL revenue accelerated: Q3 net product revenue rose 95% year over year to $41.2 million, and Autolus now expects full-year 2026 revenue of at least $150 million, above its prior guidance range.
• Commercial reach expanded ahead of plan, with 90 U.S. centers authorized against an 80-center goal and 18 centers authorized in the U.K.; management said the U.K. launch is going well.
• Gross margin improved to 57% in Q3 and 44% year to date. Management attributed the gains to higher production volumes and manufacturing efficiencies, saying the company expects continued gradual improvement.
• Cash, cash equivalents, and marketable securities totaled $248.4 million at quarter-end; the company expects funding into Q2 2028, assuming anticipated AUCATZYL sales and $25 million from the second tranche of its credit facility. Q3 net loss was $55.1 million.
• Autolus moved its first BOBCAT progressive MS data presentation to October 2027 to allow longer follow-up, citing expert feedback that at least 12 months is needed to assess clinical outcomes. Management said the study remains on track, but the data update will come later than previously anticipated.

Autolus Therapeutics Stock Performance

NASDAQ AUTL traded down $0.10 on Tuesday, reaching $1.23. 2,987,475 shares of the stock were exchanged, compared to its average volume of 1,832,511. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04. Autolus Therapeutics has a one year low of $1.12 and a one year high of $2.58. The firm has a market capitalization of $326.05 million, a PE ratio of -1.17 and a beta of 2.32. The company’s 50-day simple moving average is $1.78 and its two-hundred day simple moving average is $1.66.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Weiss Ratings lowered shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 3rd. Finally, HC Wainwright assumed coverage on shares of Autolus Therapeutics in a report on Monday, November 2nd. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.